Drug Type Small molecule drug |
Synonyms 二甲双胍格列齐特 |
Target |
Action activators, agonists |
Mechanism PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SUR agonists(Sulfonylurea receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (22 Sep 2005), |
Regulation- |
Molecular FormulaC15H21N3O3S |
InChIKeyBOVGTQGAOIONJV-UHFFFAOYSA-N |
CAS Registry21187-98-4 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus, Type 2 | China | 22 Sep 2005 |
Phase 1 | - | 21 | Metformin+Gliclazide (Metformin-Gliclazide (Fasted)) | ycncrbjuek(emetugsluk) = kpdlchvapx zitdjwgjlr (hnspemcqvm, 1599.3290) View more | - | 08 Jul 2019 | |
Metformin+Gliclazide (Metformin-Gliclazide (Fed)) | ycncrbjuek(emetugsluk) = dmgnlcfzvd zitdjwgjlr (hnspemcqvm, 2544.6658) View more |





